PRNP and prion disease: Therefore, small moleculesthat can modulate the misfolding and aggregation of the PrPC or promote the PrPSc disaggregation represent promisingtherapeutic candidates for prion diseases and other amyloidogenicdisorders.7,8 In this context, natural products have emergedas a rich source of chemical scaffolds with antiaggregation potential,offering novel opportunities for effective therapeutics.9 Examples of natural compounds with antiaggregationactivity for different amyloidogenic proteins include epigallocatechin-3-gallate,curcumin, resveratrol, and hypericin.9